Case number 1:23-cv-00490
Teva Pharmaceuticals International GmbH et al v. BendaRx Corp. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 23, 2024 | 46 | Amended Complaint* (1) |
| Jun 26, 2023 | N/A | CORRECTING ENTRY: Documents to D.I. 12 replaced per Counsels request to reflect the correct case number. (jdb) (Entered: 06/26/2023) (0) |
| Jun 23, 2023 | 12 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Main Document 12, Attachment 1, and Attachment 2 replaced on 6/26/2023) (jdb). (Entered: 06/23/2023) (7.1 Corporate Disclosure Statement) (2) |
| Jun 23, 2023 | 12 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Main Document 12, Attachment 1, and Attachment 2 replaced on 6/26/2023) (jdb). (Entered: 06/23/2023) (Text of Proposed Order) (1) |
| Jun 23, 2023 | 13 | OPENING BRIEF in Support re 12 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp..Answering Brief/Response due date per Local Rules is 7/7/2023. (Attachments: # 1 Certificate of Compliance)(Hunter, Travis) (Entered: 06/23/2023) (Certificate of Compliance) (1) |
| Jun 23, 2023 | 14 | NOTICE of Appearance by Nathalie Anne Freeman on behalf of BendaRx Corp. (Freeman, Nathalie) (Entered: 06/23/2023) (1) |
| Jun 23, 2023 | 13 | OPENING BRIEF in Support re 12 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp..Answering Brief/Response due date per Local Rules is 7/7/2023. (Attachments: # 1 Certificate of Compliance)(Hunter, Travis) (Entered: 06/23/2023) (Main Document) (25) |
| Jun 23, 2023 | 12 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Main Document 12, Attachment 1, and Attachment 2 replaced on 6/26/2023) (jdb). (Entered: 06/23/2023) (Main Document) (2) |
| May 16, 2023 | N/A | Pro Hac Vice Attorney Alex M. Grabowski for Eagle Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 05/16/2023) (0) |
| May 16, 2023 | N/A | SO ORDERED, re 11 MOTION for Pro Hac Vice Appearance of Attorney Kenneth G. Schuler, Marc N. Zubick, Alex Grabowski, and Daniel G. Brown, filed by Eagle Pharmaceuticals, Inc. Ordered by Judge Colm F. Connolly on 5/16/2023. (kmd) (Entered: 05/16/2023) (0) |
| May 15, 2023 | 11 | MOTION for Pro Hac Vice Appearance of Attorney Kenneth G. Schuler, Marc N. Zubick, Alex Grabowski, and Daniel G. Brown - filed by Eagle Pharmaceuticals, Inc.. (Joyce, Alexandra) (Entered: 05/15/2023) (6) |
| May 10, 2023 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 05/10/2023) (0) |
| May 10, 2023 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Ben Picozzi - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 05/10/2023) (4) |
| May 10, 2023 | N/A | SO ORDERED, re 9 MOTION for Pro Hac Vice Appearance of Attorney Ben Picozzi, filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. Ordered by Judge Colm F. Connolly on 5/10/2023. (kmd) (Entered: 05/10/2023) (0) |
| May 10, 2023 | N/A | Pro Hac Vice Attorney Ben V. Picozzi for Cephalon, LLC and Teva Pharmaceuticals International GmbH added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (jdb) (Entered: 05/10/2023) (0) |
| May 10, 2023 | 10 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 05/10/2023) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Main Document) (30) |
| May 5, 2023 | 7 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Ltd., Other Affiliate Capital Research Global Investors for Teva Pharmaceuticals International GmbH; Other Affiliate Teva Ltd., Other Affiliate Cupric Holding Co. LLC for Cephalon, LLC filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (vfm) (Entered: 05/05/2023) (3) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit V) (7) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit U) (14) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit T) (4) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit A) (26) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit B) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit C) (28) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit D) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit E) (29) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit F) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit G) (28) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit H) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit I) (18) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit J) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit K) (28) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit L) (22) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit M) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit N) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit O) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit P) (3) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit Q) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit R) (5) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit S) (9) |
| May 4, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Janus Henderson Group PLC, Other Affiliate BlackRock Institutional Trust Company, N.A. for Eagle Pharmaceuticals, Inc. filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (vfm) (Entered: 05/04/2023) (1) |
| May 4, 2023 | N/A | DEFICIENCY NOTICE issued by the Court to Plaintiff: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (vfm) (Entered: 05/04/2023) (0) |
| May 4, 2023 | 6 | Summons Issued as to BendaRx Corp. on 5/4/2023. (vfm) (Entered: 05/04/2023) (2) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit A) (26) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit B) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit C) (28) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit D) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit E) (29) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit F) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit G) (28) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit H) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit I) (18) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit J) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit K) (28) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit L) (22) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit M) (2) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit N) (2) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Civil Cover Sheet) (3) |
| May 4, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attached. (Attachments: # 1 Patent/Trademark Report Part 2, # 2 Patent/Trademark Report Part 3) (vfm) (Entered: 05/04/2023) (Main Document) (1) |
| May 4, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attached. (Attachments: # 1 Patent/Trademark Report Part 2, # 2 Patent/Trademark Report Part 3) (vfm) (Entered: 05/04/2023) (Patent/Trademark Report Part 2) (1) |
| May 4, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attached. (Attachments: # 1 Patent/Trademark Report Part 2, # 2 Patent/Trademark Report Part 3) (vfm) (Entered: 05/04/2023) (Patent/Trademark Report Part 3) (1) |
| May 4, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 03/23/2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 9/23/2025. (vfm) (Entered: 05/04/2023) (2) |
| May 4, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 05/04/2023) (3) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Main Document) (30) |
